Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo
Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo
复制标题
DOI：
10.1016/j.jaad.2020.03.049
复制
发表时间：
2020-07-01
影响因子：
13.8
通讯作者：
Peris, Ketty
中科院分区：
文献类型：
--
作者：
Chiricozzi, Andrea;Maurelli, Martina;Peris, Ketty
背景资料：慢性结节性荨麻疹（CNPG）是一种多因素皮肤病，以瘙痒性丘疹和结节为特征，通常对标准治疗有抵抗力，并与明显损害的生活质量相关。目的：描述dupilumab治疗局部和全身治疗均难治的CNPG成人患者的有效性和耐受性。方法：回顾性、多中心研究，包括接受dupilumab治疗至少16周的CNPG成人患者。27名CNPG患者在皮肤病变、瘙痒、失眠和生活质量方面表现出临床改善。一致比例的患者（24/27; 88.9%）接受了至少16周的连续治疗，并达到研究者总体评估评分1（11/24; 45.8%）。研究者总体评估评分至少降低2级的患者数量增加（19/24; 79.2%）。瘙痒和失眠的数字评定量表值分别从8.9下降到2.7和从8.2下降到1.7（P
Background: Chronic nodular prurigo (CNPG) is a multifactorial skin disease characterized by itchy papules and nodules, usually resistant to standard treatment and associated with markedly impaired quality of life.Objective: To describe dupilumab effectiveness and tolerability in treating adult patients with CNPG refractory to both topical and systemic therapies.Methods: Retrospective, multicenter study including adult patients affected by CNPG, who were treated with dupilumab for at least 16 weeks.Results: Twenty-seven CNPG patients showed clinical improvement in terms of skin lesions, itch, sleeplessness, and quality of life. A consistent proportion of patients (24/27; 88.9%) had at least 16-week continuous treatment and achieved Investigator Global Assessment score 1 (11/24; 45.8%). An increased number of patients achieved at least a 2-grade reduction in Investigator Global Assessment score (19/24; 79.2%). Numeric rating scale values for itch and sleeplessness decreased from 8.9 to 2.7 and from 8.2 to 1.7, respectively (P